A feedback loop of PPP and PI3K/AKT signal pathway drives regorafenib-resistance in HCC
{{output}}
Background: Hepatocellular carcinoma (HCC) is a principal type of liver cancer with high incidence and mortality rates. Regorafenib is a novel oral multikinase inhibitor for second-line therapy for advanced HCC. However, resistan... ...
